N-Butyl-[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazin-3-amine

ID: ALA3809181

PubChem CID: 127043940

Max Phase: Preclinical

Molecular Formula: C7H11N7

Molecular Weight: 193.21

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  CCCCNc1nnc2nncn2n1

Standard InChI:  InChI=1S/C7H11N7/c1-2-3-4-8-6-10-12-7-11-9-5-14(7)13-6/h5H,2-4H2,1H3,(H,8,13)

Standard InChI Key:  KDENRQFMDQXKLN-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 14 15  0  0  0  0  0  0  0  0999 V2000
   -1.0028   -1.5132    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.2917   -0.7475    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.2917    0.7475    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0028    1.5132    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3155    0.7475    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3155   -0.7475    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5889    0.0182    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.7138    1.2033    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.7138   -1.2033    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6187   -1.4919    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6267   -2.9927    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9300   -3.7369    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9380   -5.2378    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9801   -5.8328    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  1  6  2  0
  7  8  1  0
  7  9  2  0
  2  9  1  0
  3  8  2  0
  6 10  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 10 11  1  0
M  END

Alternative Forms

  1. Parent:

    ALA3809181

    ---

Associated Targets(Human)

BeWo (124 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MCF7 (126967 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Biocomponents

Calculated Properties

Molecular Weight: 193.21Molecular Weight (Monoisotopic): 193.1076AlogP: 0.13#Rotatable Bonds: 4
Polar Surface Area: 80.89Molecular Species: NEUTRALHBA: 7HBD: 1
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 12.95CX Basic pKa: CX LogP: -0.25CX LogD: -0.25
Aromatic Rings: 2Heavy Atoms: 14QED Weighted: 0.69Np Likeness Score: -2.31

References

1. Xu F, Yang ZZ, Jiang JR, Pan WG, Yang XL, Wu JY, Zhu Y, Wang J, Shou QY, Wu HG..  (2016)  Synthesis, antitumor evaluation and molecular docking studies of [1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine derivatives.,  26  (13): [PMID:27184766] [10.1016/j.bmcl.2016.05.007]
2. Xu F, Yang ZZ, Ke ZL, Xi LM, Yan QD, Yang WQ, Zhu LQ, Lin FL, Lv WK, Wu HG, Wang J, Li HB..  (2016)  Synthesis, antitumor evaluation and 3D-QSAR studies of [1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine derivatives.,  26  (19): [PMID:27597251] [10.1016/j.bmcl.2016.08.078]

Source